In vivo imaging of apoptosis
1Department of Radiology/Division of Pediatric Radiology, Lucile Salter Packard Children's Hospital, Stanford, CA 94304, USA. blankenb@stanford.edu
Abstract:
Despite over a decade of intense investigation there is still no routine method for the clinical imaging of apoptosis in oncologic patients. There have been multiple tracers proposed but none as of yet has received FDA approval. Radiolabeled annexin V is one of the few radiotracers that has been widely used in Phase II trials and is still under development. In this review we will first detail the general mechanisms involved with apoptosis and other common forms of cell death. Next we will outline the latest in vivo imaging data in animal models and humans including that obtained with radiolabeled annexin V. It is hoped that improved understanding of the complex biochemical pathways involved with cell death will lead to at least several radiopharmaceuticals with the ability to image apoptosis as part of improving the care and treatment of patients suffering from cancer.
Insights
Clinical imaging of apoptosis in cancer patients remains challenging, with no FDA-approved tracers. Radiolabeled annexin V shows promise in ongoing trials for visualizing programmed cell death.
Area of Science:
- Oncology
- Molecular Imaging
- Cell Biology
Background:
- Apoptosis imaging is crucial for cancer patient care but lacks routine clinical methods.
- Several radiotracers have been explored, yet none have achieved FDA approval.
- Radiolabeled annexin V is a leading candidate, currently in Phase II trials.
Purpose of the Study:
- To review the mechanisms of apoptosis and other cell death forms.
- To present current in vivo imaging data from animal models and human studies.
- To highlight the potential of radiopharmaceuticals for apoptosis imaging in oncology.
Main Methods:
- Review of existing literature on apoptosis and cell death pathways.
- Analysis of in vivo imaging data, including studies with radiolabeled annexin V.
- Discussion of challenges and future directions in developing imaging agents.
Main Results:
- No routine clinical method for apoptosis imaging in cancer patients exists.
- Radiolabeled annexin V has demonstrated utility in Phase II trials.
- Understanding cell death pathways is key to developing effective imaging agents.
Conclusions:
- Further research into cell death mechanisms is needed.
- Development of novel radiopharmaceuticals for apoptosis imaging is ongoing.
- Improved imaging agents will enhance cancer patient care and treatment strategies.
